Severity of COVID-19 among Hospitalized Patients: Omicron Remains a Severe Threat for Immunocompromised Hosts.
COVID-19
delta
hospitalization
immunocompromised host
omicron
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
08 12 2022
08 12 2022
Historique:
received:
14
10
2022
revised:
01
12
2022
accepted:
06
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
27
12
2022
Statut:
epublish
Résumé
The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in the general population in the context of a relatively high immunity gained through the early waves of coronavirus disease 19 (COVID-19), and vaccination campaigns. Despite this context, a significant number of patients were hospitalized, and identifying the risk factors associated with severe disease in the Omicron era is critical for targeting further preventive, and curative interventions. We retrospectively analyzed the individual medical records of 1501 SARS-CoV-2 positive hospitalized patients between 13 December 2021, and 13 February 2022, in Belgium, of which 187 (12.5%) were infected with Delta, and 1036 (69.0%) with Omicron. Unvaccinated adults showed an increased risk of moderate/severe/critical/fatal COVID-19 (crude OR 1.54; 95% CI 1.09-2.16) compared to vaccinated patients, whether infected with Omicron or Delta. In adults infected with Omicron and moderate/severe/critical/fatal COVID-19 (
Identifiants
pubmed: 36560741
pii: v14122736
doi: 10.3390/v14122736
pmc: PMC9783877
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Lancet Infect Dis. 2022 Nov;22(11):e311-e326
pubmed: 35803289
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Lancet. 2022 Jan 29;399(10323):437-446
pubmed: 35065011
N Engl J Med. 2022 Feb 17;386(7):e14
pubmed: 35108465
Nat Med. 2022 Sep;28(9):1933-1943
pubmed: 35675841
J Med Virol. 2022 Jul;94(7):2969-2976
pubmed: 35246846
Lancet. 2022 Apr 2;399(10332):1303-1312
pubmed: 35305296
Am J Pathol. 2022 Apr;192(4):642-652
pubmed: 35123975
Clin Microbiol Infect. 2022 Jun;28(6):897-899
pubmed: 35182762
N Engl J Med. 2022 Apr 7;386(14):1314-1326
pubmed: 35196424
Br J Cancer. 2022 Nov;127(10):1827-1836
pubmed: 36224402
Euro Surveill. 2022 Jan;27(4):
pubmed: 35086614
Lancet Glob Health. 2022 Jul;10(7):e961-e969
pubmed: 35597249
BMJ Open. 2022 Feb 8;12(2):e055474
pubmed: 35135773
Trop Med Int Health. 2022 Jun;27(6):564-573
pubmed: 35411997
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Med Virol. 2022 Apr;94(4):1641-1649
pubmed: 34914115
JAMA. 2022 Apr 5;327(13):1286-1288
pubmed: 35175280
Nat Med. 2022 Sep;28(9):1785-1790
pubmed: 35760080
Front Immunol. 2022 Apr 29;13:877101
pubmed: 35572518
Viruses. 2022 Jun 14;14(6):
pubmed: 35746768
Int J Infect Dis. 2022 Mar;116:38-42
pubmed: 34971823
Science. 2022 May 6;376(6593):eabn4947
pubmed: 35289632
Arch Public Health. 2020 Nov 18;78(1):121
pubmed: 33292566
Nature. 2021 May;593(7858):270-274
pubmed: 33723411
Clin Infect Dis. 2022 Jul 23;:
pubmed: 35869843
Lancet Infect Dis. 2022 Jul;22(7):967-976
pubmed: 35468331
Lancet Infect Dis. 2022 Jan;22(1):35-42
pubmed: 34461056